<Anchor>

Overnight, the University of Oxford in the UK announced that 100% antibodies were formed in a vaccine trial under development with pharmaceutical companies. Of course, this is the first clinical trial, but there is a long way to go, but it is a positive atmosphere. It has been reported that American and German companies have also succeeded in inducing immune responses.

This is reporter Kim Hye-young.

<Reporter> The

University of Oxford, UK, conducted a phase 1 clinical trial of the Corona 19 vaccine under development with the pharmaceutical company AstraZeneca, with 177 adult adults in the UK between the ages of 18 and 55. The results were positive.

A strong immune response has been formed in all clinical participants, that is, both antibodies and T cells have been formed.

The team explained that 90% of clinical participants succeeded in forming antibodies by neutralizing antibodies when the vaccine was administered once and the rest when administered twice.

[Andrew Pollard/Professor of Oxford University Research Group: We are seeing a good immune response, exactly the kind of immune response we expected. I think it will be a really important milestone in vaccine development.]

Research team believes that 70% of the medications experienced side effects such as fever and headache can be managed by antipyretic analgesics, and 50,000 including 10,000 in the UK and 30,000 in the United States. Some people said they would participate in additional clinical trials.

US pharmaceutical company Pfizer and German biotechnology company Bioentech also said they succeeded in inducing an immune response in the second trial of the Corona 19 vaccine.

Earlier, US pharmaceutical company Modena also announced that antibodies were formed in all subjects in the first clinical trial, but it seems that accurate evaluation will be possible only after the final clinical trial results confirming the safety and persistence of the vaccine.